Globenewswire·2025-12-30 01:08Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Skye securities between November 4, 2024, and October 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2]. - The deadline to move the Court to serve as lead plaintiff is January 16, 2026, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements about Skye's business and prospects, specifically regarding the effectiveness of nimacimab [4]. - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false public statements by the defendants [4]. - The lawsuit asserts that investors suffered damages when the true details about the company's prospects became known [4].